Alpha-9 Theranostics’ C$11 Million Series A Financing

Torys LLP represented Longitude Capital on the transaction.

On April 28, 2021, Alpha-9 Theranostics Inc. announced an C$11 million Series A financing to advance a portfolio of novel radiotherapeutics and diagnostics. Longitude Capital led the financing with participation from BVF Partners L.P. and insiders.

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies.

Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotechnology, medical technology and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery.

The Torys’ team comprised of Cheryl Reicin (Picture) and Brook Wong (financing/life sciences).

Involved fees earner: Cheryl Reicin – Torys LLP; Brook Wong – Torys LLP;

Law Firms: Torys LLP;

Clients: Longitude Capital Management Co LLC;

Author: Martina Bellini